For the quarter ended June 2026, Globus Medical (GMED) reported revenue of $789.61 million, up 5.9% over the same period last year. EPS came in at $1.34, compared to $0.86 in the year-ago quarter.

The reported revenue represents a surprise of +0.35% over the Zacks Consensus Estimate of $786.86 million. With the consensus EPS estimate being $1.12, the EPS surprise was +19.64%.

While investors scrutinize revenue and earnings changes year-over-year and how they compare with Wall Street expectations to determine their next move, some key metrics always offer a more accurate picture of a company's financial health.

Since these metrics play a crucial role in driving the top- and bottom-line numbers, comparing them with the year-ago numbers and what analysts estimated about them helps investors better project a stock's price performance.

Here is how Globus Medical performed in the just reported quarter in terms of the metrics most widely monitored and projected by Wall Street analysts:

  • Geographic Revenues- International: $170.51 million versus the two-analyst average estimate of $158.52 million. The reported number represents a year-over-year change of +18%.
  • Geographic Revenues- United States: $619.11 million compared to the $628.96 million average estimate based on two analysts. The reported number represents a change of +3.1% year over year.
  • Net Sales by Product Category- Enabling Technologies: $26.07 million versus the two-analyst average estimate of $37.01 million. The reported number represents a year-over-year change of -25.9%.
  • Net Sales by Product Category- Musculoskeletal Solutions: $763.54 million versus the two-analyst average estimate of $750.46 million. The reported number represents a year-over-year change of +7.5%.

View all Key Company Metrics for Globus Medical here>>>

Shares of Globus Medical have returned +5.7% over the past month versus the Zacks S&P 500 composite's +3.3% change. The stock currently has a Zacks Rank #3 (Hold), indicating that it could perform in line with the broader market in the near term.

7 Best Stocks for the Next 30 Days

Just released: Experts distill 7 elite stocks from the current list of 220 Zacks Rank #1 Strong Buys. They deem these tickers "Most Likely for Early Price Pops."

Since 1988, the full list has beaten the market more than 2X over with an average gain of +23.9% per year. So be sure to give these hand picked 7 your immediate attention. 

See them now >>

Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report

 

Globus Medical, Inc. (GMED): Free Stock Analysis Report

This article originally published on Zacks Investment Research (zacks.com).

Zacks Investment Research